These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4129814)

  • 1. The treatment of benign enlargement of the prostate with nor progesterone caproate (primostat).
    Subbiah N; Mortensen J
    Aust N Z J Surg; 1973 Feb; 42(3):304-7. PubMed ID: 4129814
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study.
    Meiraz D; Margolin Y; Lev-Ran A; Lazebnik J
    Urology; 1977 Feb; 9(2):144-8. PubMed ID: 65818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of benign prostatic hypertrophy with gestonorone caproate].
    Baranowska B; Kuzaka B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):999-1003. PubMed ID: 6209689
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monitoring the effectiveness of conservative treatment of benign prostatic hypertrophy by means of uroflowmetry].
    Tunn U; Senge T
    Z Urol Nephrol; 1978 Aug; 71(8):521-8. PubMed ID: 83057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hydroxyprogesterone caproate on experimental benign prostatic obstruction in the mouse.
    Caine M; Superstine E
    Isr J Med Sci; 1973; 9(11):1559-64. PubMed ID: 4130461
    [No Abstract]   [Full Text] [Related]  

  • 6. [Medical therapy of benign prostatic hyperplasia: cyproterone acetate vs gestonorone caproate].
    Di Silverio F
    Minerva Urol Nefrol; 1986; 38(2):163-71. PubMed ID: 2428120
    [No Abstract]   [Full Text] [Related]  

  • 7. Conservative treatment of benign prostatic hyperplasia.
    Palanca E; Juco W
    Curr Med Res Opin; 1977; 4(7):513-20. PubMed ID: 66118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depostat for benign prostatic hyperplasia?
    Drug Ther Bull; 1973 Sep; 11(19):75-6. PubMed ID: 4130364
    [No Abstract]   [Full Text] [Related]  

  • 9. [Results of treating prostatic adenoma with Depostat].
    Darenkov AF; Zakhvatov IuM; Tanko A; Ignashin NS; Varentsov GI
    Urol Nefrol (Mosk); 1980; (5):34-7. PubMed ID: 6158780
    [No Abstract]   [Full Text] [Related]  

  • 10. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gestonorone therapy of prostatic adenoma].
    Lopatkin N; Darenkow A; Sahmatow J; Tankó A; Ignaschin N; Warentsow G
    Acta Chir Acad Sci Hung; 1980; 21(4):271-8. PubMed ID: 6175122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silodosin (Rapaflo) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Conservative treatment of benign prostatic hyperplasia (author's transl)].
    Schoenenberger A; Hauri D
    Ther Umsch; 1982 Apr; 39(4):260-7. PubMed ID: 6179177
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
    Wein AJ
    J Urol; 2005 Nov; 174(5):1903. PubMed ID: 16217335
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of Depostat in prostatic adenoma on the ground of clinical and sphincterotonometric studies.
    Makrigiannis D; Gaca A
    Int Urol Nephrol; 1971; 3(1):21-9. PubMed ID: 4117491
    [No Abstract]   [Full Text] [Related]  

  • 17. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
    Song K; Choo MS; Lee KS; Han JY; Lee YS; Kim JC; Cho JS
    Urology; 2011 May; 77(5):1177-82. PubMed ID: 21256567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.
    Lee YS; Lee HN; Han JY; Choo MS; Lee KS
    J Urol; 2011 Mar; 185(3):1003-9. PubMed ID: 21251673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
    Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
    Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Endocrinological principles of conservative therapy for prostatic adenoma].
    Altwein JE; Orestano F
    Dtsch Med Wochenschr; 1975 Mar; 100(12):626-9. PubMed ID: 47287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.